Loading patent…
OwnerMitsuomi Hirashima, Nozomu Nishi +3inventors
InventorsMitsuomi Hirashima, Nozomu Nishi, Akira Yamauchi, Naoko Yoshida, Masako Seki
Estimating the term…
Galectin 9 exerts various functions depending on its localizations. On the other hand, galectin 9 is expected as participating in various biological functions. Thus, it has been required to clarify the detailed biological activities of galectin 9 and develop galectin 9-related techniques including development of drugs. Human galectin 9 shows a cytotoxic activity and an apoptosis-inducing activity on tumor cells but shows neither cytotoxic activity nor apoptosis-inducing activity on normal cells. Therefore, it is possible to employ galectin 9 proteins, galectin 9 agonists, galectin 9 antagonists, anti-galectin 9 binding protein antibodies, anti-galectin 9 binding sugar chain antibodies, galectin 9-producing, releasing or inducing substances, etc. as antitumor, antiallergic, immunosuppressive agents, drugs for autoimmune diseases, anti-inflammatory agents and active ingredients for adrenocortical steroid hormone alternatives.
A pharmaceutical or veterinary drug which comprises
An antineoplastic agent comprising an effective amount of at least one or more members selected from the group consisting of galectin 9 and peptide analogs thereof.
An anti-allergic agent comprising an effective amount of at least one or more members selected from the group consisting of galectin 9 and peptide analogs thereof.
An immunosuppressant comprising an effective amount of at least one or more members selected from the group consisting of galectin 9 and peptide analogs thereof.
A drug for auto-immune diseases, comprising an effective amount of at least one or more members selected from the group consisting of galectin 9 and peptide analogs thereof.
An anti-inflammatory agent comprising an effective amount of at least one or more members selected from the group consisting of galectin 9 and peptide analogs thereof.
An adrenocortical steroid hormone alternative comprising an effective amount of at least one or more members selected from the group consisting of galectin 9 and peptide analogs thereof.
A tumor cytotoxic therapeutic agent for malignant cells which comprises an effective amount of at least one or more members selected from the group consisting of (a) galectin 9 and Gal-9 analogs, and (b) polynucleotides each coding for galectin 9 or a polypeptide having a biological activity substantially equivalent to that owned by galectin9.
An antimetastatic agent for cancer cells, which comprises an effective amount of at least one or more members selected from the group consisting of (a) galectin 9 and Gal-9 analogs, and (b) polynucleotides each coding for galectin 9 or a polypeptide having a biological activity substantially equivalent to that owned by galectin9.
A cytotoxic drug for tumor cells which comprises an effective amount of at least one or more members selected from the group consisting of
An apoptosis-inducing drug for tumor cells, which comprises an effective amount of at least one or more members selected from the group consisting of
An apoptosis-inducing drug for immune cells, including especially activated T cells, which comprises an effective amount of at least one or more members selected from the group consisting of
A prophylactic and/or therapeutic agent for diseases or pathological conditions, caused by activated T cells, which comprises an effective amount of at least one or more members selected from the group consisting of
A galectin 9-binding factor which is selected from the group consisting of
Dependencies are inferred from the claim text.